Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

A phase 1 trial of a personalized cancer vaccine for stage III/IV clear cell renal cell carcinoma showed promising results.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...